Meaningful-Change Thresholds in CONNECT-FX Were Specific to Each Behavior Scale

CONNECT-FX did not define a behavioral responder by any improvement whatsoever. Its meaningful-change thresholds differed across social avoidance, irritability and social unresponsiveness/lethargy.

Caregiver anchors informed the thresholds

The researchers combined caregiver severity and change ratings, score distributions and qualitative caregiver research. They identified decreases of at least three points for social avoidance, nine for irritability and five for social unresponsiveness/lethargy as meaningful within-patient changes over twelve weeks.

A responder proportion differs from a mean change

A mean score can move without every participant crossing a threshold. Conversely, some participants can cross a meaningful threshold even when the overall between-group test is nonsignificant. In the full analysis set, responder comparisons were not statistically significant for the three cited domains; the irritability result was near, but did not cross, the conventional threshold.

Thresholds do not establish treatment superiority by themselves

A threshold helps interpret what changed for an individual on a particular instrument. Evidence that CBD produced more such changes than placebo requires the corresponding controlled comparison. These thresholds are not percentages of symptom elimination or criteria for cannabis impairment. They should not be transferred unchanged to a different diagnosis or rating scale. Reporting the scale, direction of change and responder definition prevents a numerical improvement from being labeled a proven CBD treatment effect.

Related analysis: the trial’s main results and limitations.

Research cited

Berry-Kravis and colleagues (2022). A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Carryover Testing Challenged the Analytical Sequence, Not the Newborn’s Exposure History

The neonatal assay’s carryover assessment examined whether a preceding high-concentration sample could affect a later measurement. It addressed an instrument-process question, not a biological exposure pathway. The protocol deliberately stressed the sequence The investigators used samples at twice the upper quantification limit followed by low-range samples. They considered contamination associated…

Spread the love

Read Article: Carryover Testing Challenged the Analytical Sequence, Not the Newborn’s Exposure History

The Paired Cord-and-Meconium Study Was Not a Survey of All Births

The forty-six specimen pairs came from archived cases in which both tests had been clinically ordered. Their cannabinoid-positive proportions were not population prevalence estimates. Selection followed the availability of paired orders Investigators sought residual meconium and cord tissue from the same newborn where testing for both matrices had been requested….

Spread the love

Read Article: The Paired Cord-and-Meconium Study Was Not a Survey of All Births

A Half-LLOQ Check Was Not the Same as Independently Determining Every Detection Limit

The neonatal cannabinoid study explicitly stated that each analyte’s detection limit was not specifically determined. It checked performance at half the lower quantification limit instead. The validation described what was actually tested The researchers verified relevant acceptance criteria and a signal-to-noise ratio of at least three at concentrations equivalent to…

Spread the love

Read Article: A Half-LLOQ Check Was Not the Same as Independently Determining Every Detection Limit

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us